{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:00:29Z","timestamp":1785463229434,"version":"3.56.0"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100023368","name":"Eisai Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl J Gynecology &amp;amp; Obste"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In the dose\u2010escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety\/antitumor activity of FZEC in patients with platinum\u2010resistant ovarian cancer (PROC) from the Study 101 expansion part.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible patients were aged \u226520\u2009years and received FZEC 0.9 or 1.2\u2009mg\/kg intravenously Q3W. Safety, objective response rate (ORR), duration of response (DOR), progression\u2010free survival (PFS), and overall survival (OS) were evaluated. Tumor assessments were performed by investigators per Response Evaluation Criteria in Solid Tumors version 1.1, and folate receptor\u2010alpha (FR\u03b1) status of tumor samples was assessed by central immunohistochemistry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 45 patients from Japan were treated. Among these patients, 24 were treated with FZEC 0.9\u2009mg\/kg and 21 with 1.2\u2009mg\/kg; 70.8% and 85.7% had FR\u03b1 expression in \u226575% of neoplastic cells, respectively. Grade (Gr) \u22653 treatment\u2010emergent adverse events were observed in nine patients (37.5%) in the 0.9\u2009mg\/kg group and in six (28.6%) in the 1.2\u2009mg\/kg group. Interstitial lung disease (ILD)\/pneumonitis occurred in 37.5% (Gr \u22653: 0%) of the 0.9\u2009mg\/kg group and 66.7% (Gr \u22653: 4.8%) of the 1.2\u2009mg\/kg group. In the 0.9 and 1.2\u2009mg\/kg groups, ORR was 25.0 and 52.4%, median (m)DOR was 10.6 and 7.6\u2009months, mPFS was 6.7 and 8.2\u2009months, and mOS was 10.5 and 20.5\u2009months, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FZEC showed promising antitumor activity, and the observed adverse events were generally manageable, with the exception of ILD, in patients with PROC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov Registration<\/jats:title>\n                    <jats:p>\n                      NCT03386942. URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03386942\">https:\/\/clinicaltrials.gov\/study\/NCT03386942<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ijgo.70676","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T12:29:40Z","timestamp":1766492980000},"page":"1334-1342","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum\u2010resistant ovarian cancer: Phase I expansion results"],"prefix":"10.1002","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-7611","authenticated-orcid":false,"given":"Kan","family":"Yonemori","sequence":"first","affiliation":[{"name":"Department of Medical Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Yunokawa","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology Cancer Institute Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Hyogo Cancer Center  Akashi Hyogo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takehara","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology NHO Shikoku Cancer Center  Matsuyama Ehime Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology Saitama Medical University International Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Hirashima","sequence":"additional","affiliation":[{"name":"Department of Gynecology Shizuoka Cancer Center  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology Hokkaido Cancer Center  Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ikezawa","sequence":"additional","affiliation":[{"name":"Clinical Data Science Department Eisai Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Otake","sequence":"additional","affiliation":[{"name":"Japan and Asia Clinical Development Department Eisai Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yusa","sequence":"additional","affiliation":[{"name":"Japan and Asia Clinical Development Department Eisai Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Miura","sequence":"additional","affiliation":[{"name":"Japan and Asia Clinical Development Department Eisai Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Nishio","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Kurume University School of Medicine  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_11_3_1","unstructured":"World Ovarian Cancer Coalition.World Ovarian Cancer Coalition Data Briefing Projects Loss of Over 4 Million Women to Ovarian Cancer by 2040. Accessed February 17 2025.https:\/\/worldovariancancercoalition.org\/world\u2010ovarian\u2010cancer\u2010coalition\u2010data\u2010briefing\u2010projects\u2010loss\u2010of\u2010over\u20104\u2010million\u2010women\u2010to\u2010ovarian\u2010cancer\u2010by\u20102040\/"},{"key":"e_1_2_11_4_1","unstructured":"National Cancer Institute.SEER. Cancer Stat Facts: Ovarian Cancer. Accessed February 17 2025.https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.011"},{"key":"e_1_2_11_6_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer. Version 3.2025. Accessed October 20 2025.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12254-024-00959-9"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1215"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.5508"},{"key":"e_1_2_11_11_1","first-page":"3567","article-title":"Alpha\u2010folate receptor expression in epithelial ovarian carcinoma and non\u2010neoplastic ovarian tissue","volume":"28","author":"Markert S","year":"2008","journal-title":"Anticancer Res"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-6-29"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.519"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2013-0309-OA"},{"key":"e_1_2_11_15_1","volume-title":"Halaven (Eribulin Mesylate) [Package Insert]","year":"2022"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14898"},{"key":"e_1_2_11_17_1","first-page":"538","article-title":"Preclinical and early clinical development of MORAb\u2010202, a folate receptor alpha\u2010targeted antibody\u2010drug conjugate, which utilizes Halaven as payload at first time","volume":"36","author":"Uenaka T","year":"2021","journal-title":"Bio Clinica"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(22)01032-2"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4740"},{"key":"e_1_2_11_20_1","volume-title":"A Report on the Natural Duration of Cancer","author":"Greenwood M","year":"1926"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.2307\/2530286"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2779-19"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6187"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9741-2"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5591"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02031-x"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5513"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9538"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.015"}],"container-title":["International Journal of Gynecology &amp; Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijgo.70676","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijgo.70676","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijgo.70676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:41:14Z","timestamp":1785462074000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1002\/ijgo.70676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/ijgo.70676"],"URL":"https:\/\/doi.org\/10.1002\/ijgo.70676","archive":["Portico"],"relation":{},"ISSN":["0020-7292","1879-3479"],"issn-type":[{"value":"0020-7292","type":"print"},{"value":"1879-3479","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"2025-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}